12/02/2019 05:00:00

Strados Labs Adds Health Leaders to Management Team

PHILADELPHIA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Strados Labs, creator of the world’s first remote respiratory monitoring platform, announced today the addition of three new executives to its management team. Strados Labs’ remote respiratory monitoring platform gives clinicians access to real-time information about changes in their patients’ lung health, allowing proactive interventions to improve pulmonary health and reduce readmissions.

“I am very excited that we have this depth of experience at Strados Labs,” said CEO and Founder Nick Delmonico, CPA, MBA. “Richard and Jason have unmatched experience in the emerging field of remote clinical monitoring, and will help Strados Labs accelerate the final development and commercialization of our platform. Dr. Glass has been a part of five successful drug launches and IPO teams, and his experience with pulmonary critical care at the University of Pennsylvania will be invaluable to our clinical validity.”

Joining the Strados Labs team are:

Richard Powers, MSE, MBA, Chief Operating Officer – Powers is the former Chief Information Officer (CIO) of CardioMEMS, a remote cardiac monitoring solution that experienced a successful $455M exit. Under his leadership at CardioMEMS, Powers and his team designed and developed a secure, cloud-based, remote healthcare monitoring disease management IoT platform powering the world’s first FDA-approved implantable wireless blood pressure sensor for patients with heart failure. He also served as CIO of Endotronix which provides hemodynamic monitoring solutions to help detect worsening heart failure. Powers received a BEE, Electrical Engineering with Highest Honor, and MSECE, Electrical and Computer Engineering, from the Georgia Institute of Technology. He completed his MBA at the Georgia Tech’s Scheller College of Business.

Mitchell Glass, MD,

Chief Medical Officer – Dr. Glass is a 30-year veteran of the pharmaceutical industry. His experience is broad, ranging from senior positions in top 10 pharmaceutical companies to investment in and management of start-ups and biotechs. His experience includes serving as VP and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, as well as Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics, Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI 1067 and was a member of the IPO team. He is the Chairman of Accolade Pharmaceuticals and has been a Director of OrphageniX Inc. (gene editing) and AVATAR Biotechnologies (biosimilars), as well as Executive VP of R&D and CMO of Invion LTD. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.

Jason Kroh, MSE, Chief Technology Officer – Kroh has a wide range of experience in medical electronics development, bringing more than two decades of experience to Strados Labs. Prior to joining Strados, he served as Vice President of New Product Development for Vero Biotech and Vice President of Hardware and Biomedical Engineering for Sarvint Technologies. He was Vice President of R&D, Electrical Engineering, for CardioMEMS, where he established and managed a multidisciplinary team of engineers and technicians to design and develop the company’s proprietary electronics platform. Kroh was the lead electrical engineer at Cybersonics Inc., where he designed and developed the electronics for the control and actuating mechanisms for therapeutic ultrasonic medical devices. Kroh holds a BS in Biomedical Engineering from Boston University and a MS in Electrical Engineering from Gannon University. He holds 26 issued U.S. patents and has co-authored multiple papers on sensing and actuation.

About Strados Labs

Strados Labs has developed the first system that objectively measures cardiopulmonary health, allowing providers to remotely monitor at-risk patients using a novel biosensor and clinically validated analytics platform. With the Strados Labs system, clinical teams can access and monitor real-time changes in lung health so they can intervene to improve patient outcomes while reducing readmissions. www.stradoslabs.com

Contact: Richard Powers, info@stradoslabs.com, 1-888-Strados

Strados - Gradient .jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
12 Feb
VELO
Hvis agendaen er at komme i en god position for en samlet overtagelse - er de vel godt på vej. I hve..
31
13 Feb
VELO
Her er nogle spørgsmål som jeg ønsker besvaret. Håber i andre vil bidrage med flere spørgsmål som JP..
24
12 Feb
PNDORA
Uden at skulle fremsætte nogen konspirationsteorier så finder jeg det personligt ganske interasant a..
23
12 Feb
GOMX
I får det seriøst til at lyde somom GomX er på vej ned og snakker dommedag 😂! Hallo bois!! Det førs..
20
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
11 Feb
VWS
MHI Vestas named as Preferred Supplier for 476 MW Baltic Eagle project in Germany http://www.mhivest..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
17
12 Feb
PNDORA
Fuldstændig uenig.Noget af Pandoras fald er absolut berettiget, ingen tvivl om det!   MEN.Pandora ha..
16
11 Feb
DSV
Der er nogen i denne her tråd, der burde skamme sig, og derefter lære at holde deres ubegavede ringe..
15
13 Feb
FING-B
Sådan skal de nye FPS kort fra Fingerprint Cards aktiveres. Smukt og ligetil https://m.youtube.com/..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Avon Products, Inc. (AVP) and Encourages AVP Investors to Contact the Firm
2
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Venator Materials PLC (VNTR) and Encourages VNTR Investors to Contact the Firm
3
Bragar Eagel & Squire, P.C. is Investigating Mattel, Inc. (MAT) on Behalf of Stockholders and Encourages MAT Investors to Contact the Firm
4
Bragar Eagel & Squire, P.C. Announces That Class Action Lawsuits Have Been Filed Against Molson Coors Brewing Company (TAP) and Encourages TAP Investors to Contact the Firm
5
200 First Responders to participate in Texas A&M Task Force 1 full-scale drill at Disaster City®

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 February 2019 16:30:00
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB1 - 2019-02-16 17:30:00 - 2019-02-16 16:30:00 - 1000 - Website: OKAY